How big is Nektar Therapeutics?

As of Jun 18, Nektar Therapeutics has a market capitalization of 108.31 million and reported net sales of 87.25 million with a net profit of -133.04 million over the latest four quarters. Shareholder's funds are 60.74 million, and total assets amount to 303.85 million.

As of Jun 18, Nektar Therapeutics has a market capitalization of 108.31 million, classifying it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 87.25 million, while the sum of net profit for the same period is -133.04 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 60.74 million, and total assets amount to 303.85 million.

What does Nektar Therapeutics do?

Nektar Therapeutics is a biopharmaceutical company focused on developing medicines for unmet medical needs, with a recent market cap of $108.31 million and quarterly net sales of $10 million, but reporting a net loss of $51 million. The company has no dividend yield and significant negative return on equity.

Overview:<BR>Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 10 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -51 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 108.31 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -8.04 <BR>Return on Equity: -860.22% <BR>Price to Book: 7.88<BR><BR>Contact Details:<BR>Address: 455 Mission Bay Blvd S, SAN FRANCISCO CA: 94158-2158 <BR>Tel: 1 415 4825300 <BR>Fax: 1 302 6555049 <BR>Website: http://www.nektar.com

Should I buy, sell or hold Nektar Therapeutics?

Who are in the management team of Nektar Therapeutics?

As of March 2022, the management team of Nektar Therapeutics includes Robert Chess (Independent Chairman), Howard Robin (President and CEO), Roy Whitfield (Lead Independent Director), and several Independent Directors: Jeff Ajer, Myriam Curet, Karin Eastham, and R. Scott Greer. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Nektar Therapeutics includes the following individuals:<BR><BR>- Mr. Robert Chess, who serves as the Independent Chairman of the Board.<BR>- Mr. Howard Robin, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Roy Whitfield, who holds the position of Lead Independent Director.<BR>- Mr. Jeff Ajer, who is an Independent Director.<BR>- Dr. Myriam Curet, who is also an Independent Director.<BR>- Ms. Karin Eastham, who serves as an Independent Director.<BR>- Mr. R. Scott Greer, who is another Independent Director.<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Is Nektar Therapeutics overvalued or undervalued?

As of August 2019, Nektar Therapeutics is considered overvalued and risky due to high valuation ratios, negative financial metrics, and significant long-term stock decline despite recent short-term gains.

As of 8 August 2019, the valuation grade for Nektar Therapeutics has moved from fair to risky, indicating a shift towards a more negative outlook. The company appears to be overvalued given its current financial metrics, particularly with a Price to Book Value of 9.02 and an EV to Sales ratio of 0.15, which suggests that the market is pricing in significant future growth despite the company's ongoing losses. Additionally, the negative ROE of -860.22% further underscores the challenges the company faces in generating returns for shareholders.<BR><BR>In comparison with peers, Nektar Therapeutics has a P/E ratio of -7.21, which is significantly lower than typical industry valuations, indicating that it is not only struggling relative to its competitors but also facing severe operational difficulties. The stock has shown impressive short-term performance, with a 1-month return of 114.22% compared to the S&P 500's 2.33%, but this should be viewed cautiously in light of the company's longer-term performance, where it has declined by 80.58% over the past five years. Overall, the combination of high valuation ratios and negative financial indicators suggests that Nektar Therapeutics is overvalued at its current price.

Is Nektar Therapeutics technically bullish or bearish?

As of September 5, 2025, Nektar Therapeutics shows a bullish technical trend, supported by strong moving averages and Bollinger Bands, despite mixed RSI readings and underperformance over longer periods compared to the S&P 500.

As of 5 September 2025, the technical trend for Nektar Therapeutics has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames. Daily moving averages indicate a bullish stance. However, the RSI shows bearish readings for both weekly and monthly periods. The KST is bullish on both time frames, and the Dow Theory indicates a mildly bullish stance on both weekly and monthly charts. The OBV shows no trend weekly but is bullish monthly.<BR><BR>Nektar Therapeutics has significantly outperformed the S&P 500 over the past week (24.49% vs. 1.05%) and month (114.22% vs. 2.33%), but has underperformed over longer periods, including the last three years (12.89% vs. 70.41%) and five years (-80.58% vs. 96.61%). Overall, the current technical stance is bullish, driven primarily by the strong performance in moving averages and Bollinger Bands.